|
1
|
Cortini M, Avnet S and Baldini N:
Mesenchymal stroma: Role in osteosarcoma progression. Cancer Lett.
405:90–99. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Xiao X, Wang W and Wang Z: The role of
chemotherapy for metastatic, relapsed and refractory osteosarcoma.
Paediatr Drugs. 16:503–512. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Maire G, Martin JW, Yoshimoto M,
Chilton-MacNeill S, Zielenska M and Squire JA: Analysis of
miRNA-gene expression-genomic profiles reveals complex mechanisms
of microRNA deregulation in osteosarcoma. Cancer Genet.
204:138–146. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mercer TR, Dinger ME and Mattick JS: Long
non-coding RNAs: Insights into functions. Nat Rev Genet.
10:155–159. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gibb EA, Brown CJ and Lam WL: The
functional role of long non-coding RNA in human carcinomas. Mol
Cancer. 10:382011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hu X, Sood AK, Dang CV and Zhang L: The
role of long noncoding RNAs in cancer: The dark matter matters.
Curr Opin Genet Dev. 48:8–15. 2018. View Article : Google Scholar
|
|
7
|
Sanchez Calle A, Kawamura Y, Yamamoto Y,
Takeshita F and Ochiya T: Emerging roles of long non-coding RNA in
cancer. Cancer Sci. 109:2093–2100. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li CH and Chen Y: Targeting long
non-coding RNAs in cancers: Progress and prospects. Int J Biochem
Cell Biol. 45:1895–1910. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cheetham SW, Gruhl F, Mattick JS and
Dinger ME: Long noncoding RNAs and the genetics of cancer. Br J
Cancer. 108:2419–2425. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gutschner T, Hämmerle M and Diederichs S:
MALAT1 - a paradigm for long noncoding RNA function in cancer. J
Mol Med (Berl). 91:791–801. 2013. View Article : Google Scholar
|
|
11
|
Ji P, Diederichs S, Wang W, Böing S,
Metzger R, Schneider PM, Tidow N, Brandt B, Buerger H, Bulk E, et
al: MALAT-1, a novel noncoding RNA, and thymosin beta4 predict
metastasis and survival in early-stage non-small cell lung cancer.
Oncogene. 22:8031–8041. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Brauze D, Mikstacka R and Pelkonen O:
Monoclonal antibody characterization of NADH- and NADPH-dependent
hydroxylation of benzo(a)pyrene in liver microsomes from
5,6-benzoflavone-induced C57Bl/6 mice. Acta Biochim Pol.
37:219–225. 1990.PubMed/NCBI
|
|
13
|
Huang NS, Chi YY, Xue JY, Liu MY, Huang S,
Mo M, Zhou SL and Wu J: Long non-coding RNA metastasis associated
in lung adenocarcinoma transcript 1 (MALAT1) interacts with
estrogen receptor and predicted poor survival in breast cancer.
Oncotarget. 7:37957–37965. 2016.PubMed/NCBI
|
|
14
|
Konishi H, Ichikawa D, Yamamoto Y, Arita
T, Shoda K, Hiramoto H, Hamada J, Itoh H, Fujita Y, Komatsu S, et
al: Plasma level of metastasis-associated lung adenocarcinoma
transcript 1 is associated with liver damage and predicts
development of hepatocellular carcinoma. Cancer Sci. 107:149–154.
2016. View Article : Google Scholar :
|
|
15
|
Guo F, Li Y, Liu Y, Wang J, Li Y and Li G:
Inhibition of metas-tasis-associated lung adenocarcinoma transcript
1 in CaSki human cervical cancer cells suppresses cell
proliferation and invasion. Acta Biochim Biophys Sin (Shanghai).
42:224–229. 2010. View Article : Google Scholar
|
|
16
|
Li Q, Pan X, Wang X, Jiao X, Zheng J, Li Z
and Huo Y: Long noncoding RNA MALAT1 promotes cell proliferation
through suppressing miR-205 and promoting SMAD4 expression in
osteosarcoma. Oncotarget. 8:106648–106660. 2017.
|
|
17
|
Wang Y, Zhang Y, Yang T, Zhao W, Wang N,
Li P, Zeng X and Zhang W: Long non-coding RNA MALAT1 for promoting
metastasis and proliferation by acting as a ceRNA of miR-144-3p in
osteosarcoma cells. Oncotarget. 8:59417–59434. 2017.PubMed/NCBI
|
|
18
|
Luo W, He H, Xiao W, Liu Q, Deng Z, Lu Y,
Wang Q, Zheng Q and Li Y: MALAT1 promotes osteosarcoma development
by targeting TGFA via MIR376A. Oncotarget. 7:54733–54743. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Farazi TA, Hoell JI, Morozov P and Tuschl
T: MicroRNAs in human cancer. Adv Exp Med Biol. 774:1–20. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cesana M, Cacchiarelli D, Legnini I,
Santini T, Sthandier O, Chinappi M, Tramontano A and Bozzoni I: A
long noncoding RNA controls muscle differentiation by functioning
as a competing endogenous RNA. Cell. 147:358–369. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang S, Sun Z, Zhou Q, Wang W, Wang G,
Song J, Li Z, Zhang Z, Chang Y, Xia K, et al: MicroRNAs, long
noncoding RNAs, and circular RNAs: Potential tumor biomarkers and
targets for colorectal cancer. Cancer Manag Res. 10:2249–2257.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dang Y, Wei X, Xue L, Wen F, Gu J and
Zheng H: Long non-coding RNA in glioma: Target miRNA and signaling
pathways. Clin Lab. 64:887–894. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gang L, Qun L, Liu WD, Li YS, Xu YZ and
Yuan DT: MicroRNA-34a promotes cell cycle arrest and apoptosis and
suppresses cell adhesion by targeting DUSP1 in osteosarcoma. Am J
Transl Res. 9:5388–5399. 2017.
|
|
25
|
Wen J, Zhao YK, Liu Y and Zhao JF:
MicroRNA-34a inhibits tumor invasion and metastasis in osteosarcoma
partly by effecting C-IAP2 and Bcl-2. Tumour Biol.
39:10104283177057612017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
27
|
Ye J, Li L, Feng P, Wan J and Li J:
Downregulation of miR-34a contributes to the proliferation and
migration of laryngeal carcinoma cells by targeting cyclin D1.
Oncol Rep. 36:390–398. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li ZH, Weng X, Xiong QY, Tu JH, Xiao A,
Qiu W, Gong Y, Hu EW, Huang S and Cao YL: miR-34a expression in
human breast cancer is associated with drug resistance. Oncotarget.
8:106270–106282. 2017.
|
|
29
|
Li Z, Dou P, Liu T and He S: Application
of long noncoding RNAs in osteosarcoma: Biomarkers and therapeutic
targets. Cell Physiol Biochem. 42:1407–1419. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li E, Zhao Z, Ma B and Zhang J: Long
noncoding RNA HOTAIR promotes the proliferation and metastasis of
osteosarcoma cells through the AKT/mTOR signaling pathway. Exp Ther
Med. 14:5321–5328. 2017.PubMed/NCBI
|
|
31
|
Li Z, Tang Y, Xing W, Dong W and Wang Z:
LncRNA, CRNDE promotes osteosarcoma cell proliferation, invasion
and migration by regulating Notch1 signaling and
epithelial-mesenchymal transition. Exp Mol Pathol. 104:19–25. 2018.
View Article : Google Scholar
|
|
32
|
Kun-Peng Z, Xiao-Long M and Chun-Lin Z:
LncRNA FENDRR sensitizes doxorubicin-resistance of osteosarcoma
cells through downregulating ABCB1 and ABCC1. Oncotarget.
8:71881–71893. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gao KT and Lian D: Long non-coding RNA
MALAT1 is an independent prognostic factor of osteosarcoma. Eur Rev
Med Pharmacol Sci. 20:3561–3565. 2016.PubMed/NCBI
|
|
34
|
Zhang ZC, Tang C, Dong Y, Zhang J, Yuan T
and Li XL: Targeting LncRNA-MALAT1 suppresses the progression of
osteosarcoma by altering the expression and localization of
β-catenin. J Cancer. 9:71–80. 2018. View Article : Google Scholar :
|
|
35
|
Huo Y, Li Q, Wang X, Jiao X, Zheng J, Li Z
and Pan X: MALAT1 predicts poor survival in osteosarcoma patients
and promotes cell metastasis through associating with EZH2.
Oncotarget. 8:46993–47006. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Dong Y, Liang G, Yuan B, Yang C, Gao R and
Zhou X: MALAT1 promotes the proliferation and metastasis of
osteosarcoma cells by activating the PI3K/Akt pathway. Tumour Biol.
36:1477–1486. 2015. View Article : Google Scholar
|
|
37
|
Cai X, Liu Y, Yang W, Xia Y, Yang C, Yang
S and Liu X: Long noncoding RNA MALAT1 as a potential therapeutic
target in osteosarcoma. J Orthop Res. 34:932–941. 2016. View Article : Google Scholar
|
|
38
|
Sen R, Ghosal S, Das S, Balti S and
Chakrabarti J: Competing endogenous RNA: The key to
posttranscriptional regulation. ScientificWorldJournal.
2014.896206:2014.
|
|
39
|
Liz J and Esteller M: lncRNAs and
microRNAs with a role in cancer development. Biochim Biophys Acta.
1859.169–176. 2016.
|
|
40
|
Zhang R and Xia T: Long non-coding RNA
XIST regulates PDCD4 expression by interacting with miR-21-5p and
inhibits osteosarcoma cell growth and metastasis. Int J Oncol.
51:1460–1470. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Leucci E, Patella F, Waage J, Holmstrøm K,
Lindow M, Porse B, Kauppinen S and Lund AH: microRNA-9 targets the
long non-coding RNA MALAT1 for degradation in the nucleus. Sci Rep.
3:25352013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
He L, He X, Lim LP, de Stanchina E, Xuan
Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, et al: A microRNA
component of the p53 tumour suppressor network. Nature.
447:1130–1134. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Bommer GT, Gerin I, Feng Y, Kaczorowski
AJ, Kuick R, Love RE, Zhai Y, Giordano TJ, Qin ZS, Moore BB, et al:
p53-mediated activation of miRNA34 candidate tumor-suppressor
genes. Curr Biol. 17:1298–1307. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Misso G, Di Martino MT, De Rosa G, Farooqi
AA, Lombardi A, Campani V, Zarone MR, Gullà A, Tagliaferri P,
Tassone P, et al: Mir-34: A new weapon against cancer? Mol Ther
Nucleic Acids. 3:e1942014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wang Y, Jia LS, Yuan W, Wu Z, Wang HB, Xu
T, Sun JC, Cheng KF and Shi JG: Low miR-34a and miR-192 are
associated with unfavorable prognosis in patients suffering from
osteosarcoma. Am J Transl Res. 7:111–119. 2015.PubMed/NCBI
|
|
46
|
Li Z, Wang C, Prendergast GC and Pestell
RG: Cyclin D1 functions in cell migration. Cell Cycle. 5:2440–2442.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ramos-García P, González-Moles MA,
González-Ruiz L, Ruiz-Ávila I, Ayén Á and Gil-Montoya JA:
Prognostic and clinicopathological significance of cyclin D1
expression in oral squamous cell carcinoma: A systematic review and
meta-analysis. Oral Oncol. 83:96–106. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Luo J, Xu LN, Zhang SJ, Jiang YG, Zhuo DX,
Wu LH, Jiang X and Huang Y: Downregulation of LncRNA-RP11-317J10.2
promotes cell proliferation and invasion and predicts poor
prognosis in colorectal cancer. Scand J Gastroenterol. 53:38–45.
2018. View Article : Google Scholar
|
|
49
|
Inoue K and Fry EA: Aberrant expression of
cyclin D1 in cancer. Signal Transduct Insights. 4:1–13. 2015.
View Article : Google Scholar
|
|
50
|
Ju X, Casimiro MC, Gormley M, Meng H, Jiao
X, Katiyar S, Crosariol M, Chen K, Wang M, Quong AA, et al:
Identification of a cyclin D1 network in prostate cancer that
antagonizes epithelial-mesenchymal restraint. Cancer Res.
74:508–519. 2014. View Article : Google Scholar :
|
|
51
|
Cai CK, Zhao GY, Tian LY, Liu L, Yan K, Ma
YL, Ji ZW, Li XX, Han K, Gao J, et al: miR-15a and miR-16-1
downregulate CCND1 and induce apoptosis and cell cycle arrest in
osteosarcoma. Oncol Rep. 28:1764–1770. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Sun F, Fu H, Liu Q, Tie Y, Zhu J, Xing R,
Sun Z and Zheng X: Downregulation of CCND1 and CDK6 by miR-34a
induces cell cycle arrest. FEBS Lett. 582:1564–1568. 2008.
View Article : Google Scholar : PubMed/NCBI
|
